Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411437 · ClinicalTrials.gov registry record · Phase 4
Effects Of Detrol LA On Memory And Cognition In Elderly Population
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
NCT00411437 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 220 participants.
The verdict
NCT00411437, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
Study Summary
The primary purpose of the trial is to show that tolterodine ER has no effect on memory and other cognitive abilities in an elderly population
Interventions
- DRUG Tolterodine ER
- DRUG Oxybutynin ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411437
The ClinicalTrials.gov registry entry for NCT00411437 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tolterodine ER is the first listed.
NCT00411437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00411437 about?
NCT00411437 is a clinical study titled "Effects Of Detrol LA On Memory And Cognition In Elderly Population". The primary purpose of the trial is to show that tolterodine ER has no effect on memory and other cognitive abilities in an elderly population
What is the current status of trial NCT00411437?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2006-12. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00411437?
The interventions under investigation include: Tolterodine ER (DRUG), Oxybutynin ER (DRUG).
Who is sponsoring clinical trial NCT00411437?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.